Skip to main content
. 2017 Sep 8;8(44):77761–77770. doi: 10.18632/oncotarget.20780

Figure 2. Performance validation of the six-lncRNA signature in the validation cohort.

Figure 2

(A) Kaplan-Meier survival curves of overall survival between high-risk group and low-risk group. (B) The prediction performance for three- and five-year overall survival by the ROC analysis.